Furthermore, the addition of a second-generation anti-androgen, abiraterone, has shown to improve overall survival (OS) in a post hoc analysis in men with N1 prostate cancer.9 Although the incidence of N1 prostate cancer was historically low, the rising incidence of these advanced cases in light of reduced PSA screenings as well as the recent guideline recommendation8 of definitive EBRT plus ADT as the preferred treatment option highlight the need to optimize management and identify factors associated with long-term outcomes in these patients. The gene discussed is KLK3; the disease is Familial prostate cancer.